Immunosuppressive management following intestinal transplantation in adult patients.
Mueller
A R
AR
Department of Surgery, Charité, Campus Virchow Clinic, Humboldt University of Berlin, Berlin, Germany.
Pascher
A
A
Platz
K P
KP
Schulz
R J
RJ
Rayes
N
N
Seehofer
D
D
Nüssler
N C
NC
Junge
G
G
Neumann
U P
UP
Klupp
J
J
Dignass
A
A
Radtke
C
C
Neuhaus
P
P
D000328:Adult; D001706:Biopsy; D004651:Employment; D005176:Factor XIII / Q000627:therapeutic use; D006084:Graft Rejection / Q000453:epidemiology; D006085:Graft Survival / Q000502:physiology; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007239:Infections / Q000453:epidemiology; D007413:Intestinal Mucosa / Q000473:pathology; D007421:Intestine, Small / Q000637:transplantation*; D008875:Middle Aged; D016853:Muromonab-CD3 / Q000627:therapeutic use; D018579:Patient Selection; D011183:Postoperative Complications / Q000453:epidemiology; D011788:Quality of Life; D012778:Short Bowel Syndrome / Q000601:surgery; D014019:Tissue Donors; D014184:Transplantation, Homologous / Q000276:immunology*
D016756:Immunoglobulins, Intravenous; D007166:Immunosuppressive Agents; D016853:Muromonab-CD3; D005176:Factor XIII